Safety and Maximum Tolerated Dose of Recombinant Soluble Human CD4 in AIDS and ARC Patients
CD4 Antigens
Blood-Borne Infections+14
+ Urogenital Diseases
+ Genital Diseases
Treatment Study
Summary
This study focuses on a treatment for patients diagnosed with AIDS or AIDS-related complex (ARC). The treatment in question is recombinant soluble human CD4 (rCD4) therapy. The main goal is to understand the safety of this therapy and to find the highest dose that patients can tolerate without significant side effects. This research is important as it could potentially provide a new treatment option for those living with AIDS or ARC, improving their quality of life and addressing the challenges associated with these conditions. During the study, participants will receive rCD4 therapy through a continuous infusion. The effects of this treatment on the virus will be observed to get a preliminary indication of its antiviral properties. The study will also measure the steady state serum levels of rCD4, which refers to the consistent level of the therapy in the blood after continuous infusion. This will help researchers understand how the body responds to the treatment.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location